Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

235 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Health-related quality of life and cost-effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design.
Sullivan MD, Anderson RT, Aron D, Atkinson HH, Bastien A, Chen GJ, Feeney P, Gafni A, Hwang W, Katz LA, Narayan KM, Nwachuku C, O'Connor PJ, Zhang P; ACCORD Study Group. Sullivan MD, et al. Among authors: katz la. Am J Cardiol. 2007 Jun 18;99(12A):90i-102i. doi: 10.1016/j.amjcard.2007.03.027. Epub 2007 Apr 13. Am J Cardiol. 2007. PMID: 17599429 Clinical Trial.
Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial.
O'Connor PJ, Narayan KM, Anderson R, Feeney P, Fine L, Ali MK, Simmons DL, Hire DG, Sperl-Hillen JM, Katz LA, Margolis KL, Sullivan MD. O'Connor PJ, et al. Among authors: katz la. Diabetes Care. 2012 Jul;35(7):1479-81. doi: 10.2337/dc11-1868. Epub 2012 May 14. Diabetes Care. 2012. PMID: 22584134 Free PMC article. Clinical Trial.
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.
Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O'Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I; ACCORD trial group. Ismail-Beigi F, et al. Lancet. 2010 Aug 7;376(9739):419-30. doi: 10.1016/S0140-6736(10)60576-4. Epub 2010 Jun 30. Lancet. 2010. PMID: 20594588 Free PMC article. Clinical Trial.
Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients.
Ismail-Beigi F, Craven TE, O'Connor PJ, Karl D, Calles-Escandon J, Hramiak I, Genuth S, Cushman WC, Gerstein HC, Probstfield JL, Katz L, Schubart U; ACCORD Study Group. Ismail-Beigi F, et al. Kidney Int. 2012 Mar;81(6):586-94. doi: 10.1038/ki.2011.415. Epub 2011 Dec 14. Kidney Int. 2012. PMID: 22166848 Free PMC article. Clinical Trial.
Effects of intensive blood-pressure control in type 2 diabetes mellitus.
ACCORD Study Group; Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. ACCORD Study Group, et al. N Engl J Med. 2010 Apr 29;362(17):1575-85. doi: 10.1056/NEJMoa1001286. Epub 2010 Mar 14. N Engl J Med. 2010. PMID: 20228401 Free PMC article. Clinical Trial.
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189511 Clinical Trial.
Effects of Intensive BP Control in CKD.
Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL, Cushman WC, Hawfield AT, Johnson KC, Lewis CE, Oparil S, Rocco MV, Sink KM, Whelton PK, Wright JT Jr, Basile J, Beddhu S, Bhatt U, Chang TI, Chertow GM, Chonchol M, Freedman BI, Haley W, Ix JH, Katz LA, Killeen AA, Papademetriou V, Ricardo AC, Servilla K, Wall B, Wolfgram D, Yee J; SPRINT Research Group. Cheung AK, et al. Among authors: katz la. J Am Soc Nephrol. 2017 Sep;28(9):2812-2823. doi: 10.1681/ASN.2017020148. Epub 2017 Jun 22. J Am Soc Nephrol. 2017. PMID: 28642330 Free PMC article. Clinical Trial.
Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT).
Rocco MV, Sink KM, Lovato LC, Wolfgram DF, Wiegmann TB, Wall BM, Umanath K, Rahbari-Oskoui F, Porter AC, Pisoni R, Lewis CE, Lewis JB, Lash JP, Katz LA, Hawfield AT, Haley WE, Freedman BI, Dwyer JP, Drawz PE, Dobre M, Cheung AK, Campbell RC, Bhatt U, Beddhu S, Kimmel PL, Reboussin DM, Chertow GM; SPRINT Research Group. Rocco MV, et al. Among authors: katz la. Am J Kidney Dis. 2018 Mar;71(3):352-361. doi: 10.1053/j.ajkd.2017.08.021. Epub 2017 Nov 20. Am J Kidney Dis. 2018. PMID: 29162340 Free PMC article. Clinical Trial.
Association of Total Medication Burden With Intensive and Standard Blood Pressure Control and Clinical Outcomes: A Secondary Analysis of SPRINT.
Derington CG, Gums TH, Bress AP, Herrick JS, Greene TH, Moran AE, Weintraub WS, Kronish IM, Morisky DE, Trinkley KE, Saseen JJ, Reynolds K, Bates JT, Berlowitz DR, Chang TI, Chonchol M, Cushman WC, Foy CG, Herring CT, Katz LA, Krousel-Wood M, Pajewski NM, Tamariz L, King JB; SPRINT Research Group. Derington CG, et al. Among authors: katz la. Hypertension. 2019 Aug;74(2):267-275. doi: 10.1161/HYPERTENSIONAHA.119.12907. Epub 2019 Jul 1. Hypertension. 2019. PMID: 31256717 Free PMC article.
235 results